Memory Pharmaceuticals

01 Nov 1999

Memory Pharmaceuticals intends to discover and develop drugs to treat mild-to-moderate dementia caused by disease, traumatic injury, or aging. Its technology is based on the work of Dr. Eric Kandel, one of the pioneers in discovering the molecular mechanisms of long-term memory formation.

Scientific Advisory Board: Eric R. Kandel, MD (Columbia University); Walter Gilbert, PhD (Harvard University); Larry R. Squire, PhD (University of California, San Diego); Richard P. Mayeux, MD (Columbia-Presbyterian Medical Center); Steven Siegelbaum, PhD (Columbia University); Joseph Schlessinger, PhD (New York University Medical Center)

The name says it all: Memory Pharmaceuticals Corp. is on a mission to create therapeutic products for individuals with...